CX-072 (PD-L1-targeting Probody therapeutic)
CX-072 is a PD-L1-targeting Probody therapeutic for the treatment of cancer, currently being evaluated in a Phase 1/2 clinical trial. The study is evaluating CX-072 as monotherapy and in combination with Yervoy® (ipilimumab) or Zelboraf® (vemurafenib) in patients with certain cancers.
Purpose: The purpose of this first-in-human study of CX-072 is to characterize the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and antitumor activity of CX-072 administered intravenously (IV) as a single agent or in combination with ipilimumab or vemurafenib in adult subjects with advanced or recurrent solid tumors or lymphomas.
Start Date: January 2017
Estimated enrollment: 150 patients
For patients interested in learning if you are eligible for the trial, please visit clinicaltrials.gov.